Physician profile
Anthony E Brown
NPI 1821187295
$1,990.25
in general payments reported to CMS, 2019-2025
23 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $64.30 · 2021: $20.63 · 2023: $504 · 2024: $422 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $279.71 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $271.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $250.24 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Lilly USA, LLC | $186.20 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Inspire Medical Systems, INC. | $72.21 | 2024-2025 | Inspire |
| Dynavax Technologies Corporation | $57.33 | 2019-2025 | Heplisav-B |
| Ibsa Pharma INC. | $54.79 | 2025 | Flector, Licart, Tirosint |
| Merck Sharp & Dohme LLC | $45.37 | 2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $41.91 | 2023-2025 | |
| Abbott Laboratories | $38.79 | 2023-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $32.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $30.89 | 2019-2024 | Farxiga |
| Arbor Pharmaceuticals, INC. | $28.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.08 | 2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries Lp | $23.76 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $20.63 | 2021 | |
| Biogen, INC. | $18.74 | 2025 | Spinraza |
| Abbvie INC. | $18.58 | 2025 | |
| Esperion Therapeutics, INC. | $18.06 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2019 | |
| Genentech USA, INC. | $13.48 | 2019 | |
| Gilead Sciences, INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.